Dengue serotype 2 attenuated strain
US7641908B2 · kind B2 · utility
10Cited by
0References
10Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jun 15, 2006 |
| Grant date | Jan 5, 2010 |
| Priority date | — |
| Expiry date | Nov 8, 2026 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to live attenuated VDV2 (VERO-Derived Vaccine Dengue serotype 2) strains which have been derived from the wild-type dengue-2 strain 16681 by passaging on PDK and Vero cells. The invention further relates to a vaccine composition which comprises a VDV2 strain.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.